Folltropin-V is a follicle stimulating hormone (FSH) used to induce superovulation in cattle to facilitate embryo transfer. "Folltropin-V already enjoys a significant presence in the world market for superovulatory technology, with more than 70 percent market share," said Andrew Grant, President of Bioniche Animal Health. "China represents a growing market with a population of 1.3 billion and an ever-increasing demand for dairy and meat products, where bovine genetic improvement - particularly involving dairy cattle - is a high priority. Currently, the cattle population in China is estimated to be 187 million head and Folltropin-V will be our lead product for this vast market. The Company is pursuing further Folltropin-V registrations for the developed markets of France and Germany, as well as the developing market in India."

The product has been available in North America, Latin America, Australia, New Zealand, and parts of Europe for a number of years. It was also previously available in China on a limited basis under import permit, but could not be properly promoted until now.

"The Company's recent listing on the Australian Securities Exchange was strategic in enabling better access to the large and growing Asian market," said Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences. "With the ASX listing, we have the opportunity to better access Asian customers and expand our networking for potential technology partnerships there."